Try a new search

Format these results:

Searched for:

in-biosketch:true

person:bangas01

Total Results:

827


Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: an updated review of literature

Chatterjee, Saurav; Kumbhani, Dharam Jaydeep; Sardar, Partha; Chakraborty, Anasua; Biondi-Zoccai, Giuseppe; Sabharwal, Manpreet Singh; Ro, Richard; Pratap, Balaji; Bavishi, Chirag P; Bangalore, Sripal
Recent trials have highlighted the comparable mortality benefits and durability of the results for patients with severe aortic stenosis (AS) and high surgical risk managed with either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (AVR). Various national guidelines and international regulatory bodies have approved TAVR, thereby leading to potential wide usage and dissemination of this technique worldwide. Quality-of-life outcomes, in spite of being an important measure of success and acceptability of the procedure, have not been publicized as extensively. For high risk patients with severe AS, implementation of TAVR has resulted in comparable survival, but different and novel adverse events compared with AVR. We present an updated review focusing on the quality-of-life outcomes and issues with this new and important procedural approach.
PMID: 24585114
ISSN: 1523-3782
CID: 967402

A prospective study of arm circumference and risk of death in Bangladesh

Chen, Yu; Ge, Wenzhen; Parvez, Faruque; Bangalore, Sripal; Eunus, Mahbub; Ahmed, Alauddin; Islam, Tariqul; Rakibuz-Zaman, Muhammad; Hasan, Rabiul; Argos, Maria; Levy, Diane; Sarwar, Golam; Ahsan, Habibul
BACKGROUND:: Epidemiological studies have observed protective effects of mid-upper arm circumference (MUAC) against all-cause mortality mostly in Western populations. However, evidence on cause-specific mortality is limited. METHODS:: The sample included 19 575 adults from a population-based cohort study in rural Bangladesh, who were followed up for an average of 7.9 years for mortality. Cox proportional hazards regression was used to evaluate the effect of MUAC, as well as the joint effect of body mass index (BMI) and MUAC, on the risk of death from any cause, cancer and cardiovascular disease (CVD). RESULTS:: During 154 664 person-years of follow-up, 744 deaths including 312 deaths due to CVD and 125 deaths due to cancer were observed. There was a linear inverse relationship of MUAC with total and CVD mortality. Each 1-cm increase in MUAC was associated a reduced risk of death from any cause [hazard ratio (HR) = 0.85; 95% confidence interval (C), 0.81-0.89) and CVD (HR = 0.87; 95% CI, 0.80-0.94), after controlling for potential confounders. No apparent relationship between MUAC and the risk of death from cancer was observed. Among individuals with a low BMI (<18.5 kg/m2), a MUAC less than 24 cm was associated with increased risk for all-cause (HR = 1.81; 95% CI, 1.52-2.17) and CVD mortality (HR = 1.45; 95% CI, 1.11-1.91). CONCLUSIONS:: MUAC may play a critical role on all-cause and CVD mortality in lean Asians.
PMCID:4121562
PMID: 24713183
ISSN: 0300-5771
CID: 967412

Optimal aspirin dose in acute coronary syndromes: an emerging consensus

Dinicolantonio, James J; Norgard, Nicholas B; Meier, Pascal; Lavie, Carl J; O'Keefe, James H; Niazi, Asfandyar K; Chatterjee, Saurav; Packard, Kathleen A; D'Ascenzo, Fabrizio; Cerrato, Enrico; Biondi-Zoccai, Giuseppe; Bangalore, Sripal; Fuchs, Flavio D; Serebruany, Victor L
Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.
PMID: 24762255
ISSN: 1479-6678
CID: 967422

Embolic protection devices

Bangalore, Sripal; Bhatt, Deepak L
PMID: 24778124
ISSN: 0009-7322
CID: 967432

Aspiration thrombectomy in patients undergoing primary angioplasty: Totality of data to 2013

Kumbhani, Dharam J; Bavry, Anthony A; Desai, Milind Y; Bangalore, Sripal; Byrne, Robert A; Jneid, Hani; Bhatt, Deepak L
Objectives: We sought to update our meta-analysis on clinical outcomes with aspiration thrombectomy prior to primary percutaneous coronary intervention (PPCI) compared with conventional PPCI alone due to the availability of additional trial data. Background: The clinical efficacy of adjunctive aspiration thrombectomy in ST-elevation myocardial infarction (STEMI) patients undergoing PPCI remains controversial. A recent large-scale randomized trial showed no benefit in terms of mortality at 30 days. Methods: Clinical trials that randomized STEMI patients to aspiration thrombectomy prior to PPCI compared with conventional PPCI alone were included. Results: A total of 11,321 patients from 20 randomized controlled trials were included. The composite major adverse cardiac event (MACE) endpoint was lower in the aspiration thrombectomy arm compared with conventional PPCI alone (Risk Ratio [RR]=0.81, 95% CI 0.70-0.94; p=0.006). Although all-cause mortality was similar between the adjunctive aspiration thrombectomy arm and PPCI arms (RR=0.83, 95% CI 0.67-1.01; p=0.06), late mortality (6-12 months) was significantly reduced (RR=0.64; 95% CI 0.44-0.92; p=0.016). Reinfarction (RR=0.64, 95% CI 0.44-0.92; p=0.017) and stent thrombosis (RR=0.54; 95% CI 0.32-0.91; p=0.021) were similarly lower. Differences in target vessel revascularization were of borderline significance (RR=0.83, 95% CI 0.68-1.01; p=0.06) Conclusions: Our meta-analysis including all randomized controlled trials on aspiration thrombectomy to date demonstrates a significant reduction in adverse clinical outcomes including stent thrombosis compared with conventional PCI alone. (c) 2014 Wiley Periodicals, Inc.
PMID: 24782350
ISSN: 1522-1946
CID: 967442

Blood pressure reduction in elderly patients with hypertension decreases risk of adverse cardiovascular outcomes

Bangalore, Sripal; Doran, Bethany
PMID: 24785469
ISSN: 1356-5524
CID: 967452

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

Bangalore, Sripal; Fayyad, Rana; Hovingh, G Kees; Laskey, Rachel; Vogt, Liffert; Demicco, David A; Waters, David D
A recent study has shown an association between high-potency statins and risk of acute kidney injury. However, these data are from observational studies, and it is not clear if similar signal is seen from randomized controlled trials. We evaluated the risk of renal-associated serious adverse events (SAEs) using statins versus placebo trials and the high-dose versus low-dose statin trials that were available to us. The outcome of interest was renal-related SAEs. The incidence of adverse events relating to kidney injury was determined through review of the adverse event database. The following outcomes were evaluated: (1) renal-related SAEs within 120 days of randomization (primary outcome), (2) renal-related SAEs after 120 days of randomization (secondary), and (3) drug discontinuation due to renal-related SAEs (secondary). There was no difference in the incidence of renal-related SAEs at 120 days (0.04% vs 0.10%, p = 0.162) between atorvastatin and placebo in the 24 placebo-controlled trials (10,345 patients on atorvastatin (10 to 80 mg/day) versus 8,945 patients on placebo) or in the high-dose versus low-dose statin trials including the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study (0.05% vs 0.02%, p = 0.625) or the Treating to New Targets (TNT) trial (0.0% vs 0.04%, p = 0.500) trial. Results were similar for renal-related SAEs after 120 days (placebo controlled trials [0.38% vs 0.36%, p = 0.905], IDEAL trial [0.56% vs 0.65%, p = 0.683], or the TNT trial [0.76% vs 1.04%, p = 0.168]) and for drug withdrawal due to renal-related SAE (placebo controlled trials [0.05% vs 0.04%, p = 1.00], IDEAL trial [0.02% vs 0.0%, p = 0.499], or the TNT trial [0.08% vs 0.12%, p = 0.754]). In conclusion, the results from clinical trials with data from 149,882 patient-years of follow-up fail to show any increase in renal-related SAEs with statins compared with controls.
PMID: 24793673
ISSN: 0002-9149
CID: 967462

Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events Registry

Bangalore, Sripal; Pencina, Michael J; Kleiman, Neal S; Cohen, David J
BACKGROUND: The use of bivalirudin versus unfractionated heparin monotherapy in patients without ST-segment-elevation myocardial infarction is not well defined. METHODS AND RESULTS: The study population consisted of patients enrolled in the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry with either non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease, who underwent percutaneous coronary intervention with either unfractionated heparin or bivalirudin monotherapy. Propensity score matching was used to adjust for baseline characteristics. The primary bleeding (in-hospital composite bleeding-access site bleeding, thrombolysis in myocardial infarction major/minor bleeding, or transfusion) and primary (in-hospital death/myocardial infarction) and secondary ischemic outcomes (death/myocardial infarction/unplanned repeat revascularization at 12 months) were evaluated. Propensity score matching yielded 1036 patients with non-ST-segment-elevation acute coronary syndromes and 2062 patients with stable ischemic heart disease. For the non-ST-segment-elevation acute coronary syndrome cohort, bivalirudin use was associated with lower bleeding (difference, -3.3% [-0.8% to -5.8%]; P=0.01; number need to treat=30) without increase in either primary (difference, 1.2% [4.1% to -1.8%]; P=0.45) or secondary ischemic outcomes, including stent thrombosis (difference, 0.0% [1.3% to -1.3%]; P=1.00). Similarly, in the stable ischemic heart disease cohort, bivalirudin use was associated with lower bleeding (difference, -1.8% [-0.4% to -3.3%]; P=0.01; number need to treat=53) without increase in either primary (difference, 0.4% [2.3% to -1.5%]; P=0.70) or secondary ischemic outcomes, including stent thrombosis (difference, 0.0% [0.7% to -0.7%]; P=1.00) when compared with unfractionated heparin monotherapy. CONCLUSIONS: Among patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease undergoing percutaneous coronary intervention, bivalirudin use during percutaneous coronary intervention when compared with unfractionated heparin monotherapy was associated with lower bleeding without significant increase in ischemic outcomes or stent thrombosis.
PMID: 24736878
ISSN: 1941-7640
CID: 909242

Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack

Bangalore, Sripal; Schwamm, Lee; Smith, Eric E; Singh, Inder M; Liang, Li; Fonarow, Gregg C; Bhatt, Deepak L
BACKGROUND: Patients with stroke or transient ischemic attack are at increased risk of recurrent stroke. Transient ischemic attack is a harbinger for stroke merely hours to days after the initial transient ischemic attack. There is thus a narrow window of opportunity to initiate evidence-based therapies for secondary prevention of stroke. Our objective was to assess hospital adherence at discharge to secondary prevention measures after transient ischemic attack or ischemic stroke. METHODS: Observational study of patients in the Get With The Guidelines-Stroke registry from 2007 to 2011. Patients were divided into 2 cohorts based on presentation- transient ischemic attack vs. ischemic stroke. Adherence to evidence-based secondary prevention and other quality measures were assessed. RESULTS: Among the 858,835 patients with transient ischemic attack or ischemic stroke, 259,319 (30%) patients presented with a transient ischemic attack and 599,516 (70%) patients presented with an ischemic stroke. After adjusting for patient and hospital characteristics, adherence to secondary prevention measures was consistently lower for the transient ischemic attack cohort (vs. ischemic stroke cohort) who had lower odds of being discharged on antithrombotics (Odds Ratio (OR)=0.63; 95% confidence interval (CI) 0.59-0.66; P<0.0001), anticoagulants for atrial fibrillation (OR=0.65; 95% CI 0.61-0.68; P<0.0001), lipid lowering medication for LDL >100 mg/dl (OR=0.52; 95% CI 0.50-0.54; P<0.0001), intensive statin therapy (OR=0.74; 95% CI 0.72-0.76; P<0.0001), LDL cholesterol measurement (OR=0.66; 95% CI 0.64-0.68; P<0.0001), smoking cessation counseling (OR=0.83; 95% CI 0.78-0.89; P<0.0001), stroke education (OR=0.71; 95% CI 0.69-0.73; P<0.0001), or weight loss recommendations (OR=0.88; 95% CI 0.85-0.90; P<0.0001). The adherence to evidence-based therapies increased significantly (P<0.0001) over time (2007-2011) for both the cohorts, but the increasing trend was consistently lower for patients who presented with transient ischemic attack. CONCLUSIONS: In patients surviving an ischemic stroke or transient ischemic attack, adherence to evidence-based secondary prevention discharge measures were consistently less for patients with transient ischemic attack, thus representing a missed opportunity at instituting preventive measures to reduce the risk of recurrent stroke.
PMID: 24681258
ISSN: 0002-9343
CID: 909252

Renal denervation for resistant hypertension? [Comment]

Messerli, Franz H; Bangalore, Sripal
PMID: 24678938
ISSN: 0028-4793
CID: 909262